American Century Companies Inc. increased its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 99.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 963,517 shares of the medical equipment provider’s stock after purchasing an additional 479,375 shares during the period. American Century Companies Inc. owned approximately 2.18% of ABIOMED worth $180,573,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of ABIOMED by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 14,094 shares of the medical equipment provider’s stock valued at $2,019,000 after purchasing an additional 680 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of ABIOMED by 9.0% in the second quarter. Wells Fargo & Company MN now owns 15,712 shares of the medical equipment provider’s stock worth $2,252,000 after acquiring an additional 1,297 shares during the period. FMR LLC acquired a new position in shares of ABIOMED in the second quarter worth approximately $32,609,000. Parametric Portfolio Associates LLC lifted its stake in shares of ABIOMED by 1.2% in the second quarter. Parametric Portfolio Associates LLC now owns 43,532 shares of the medical equipment provider’s stock worth $6,238,000 after acquiring an additional 531 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of ABIOMED by 2.8% in the second quarter. Dimensional Fund Advisors LP now owns 141,970 shares of the medical equipment provider’s stock worth $20,343,000 after acquiring an additional 3,830 shares during the period. Institutional investors own 90.35% of the company’s stock.
ABIOMED, Inc. (NASDAQ:ABMD) opened at $233.99 on Wednesday. The firm has a market capitalization of $10,348.61, a PE ratio of 118.18, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. ABIOMED, Inc. has a one year low of $107.60 and a one year high of $255.42.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.50 by $0.20. The firm had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The company’s revenue was up 34.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 EPS. equities analysts forecast that ABIOMED, Inc. will post 2.39 EPS for the current year.
Several equities analysts have issued reports on the company. Leerink Swann boosted their price target on ABIOMED to $300.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. BTIG Research reissued a “hold” rating on shares of ABIOMED in a research note on Sunday, February 4th. Morgan Stanley boosted their price objective on ABIOMED from $204.00 to $259.00 and gave the company an “equal weight” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded ABIOMED from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 6th. Finally, Piper Jaffray Companies reiterated a “positive” rating and set a $300.00 price target (up previously from $220.00) on shares of ABIOMED in a report on Thursday, February 1st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. ABIOMED currently has a consensus rating of “Buy” and an average target price of $263.86.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/american-century-companies-inc-boosts-position-in-abiomed-inc-abmd.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.